Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Zentalis prices $80.5 million stock offering at $3.50 a shareAug 14FinancingazenosertibZentalis Pharmaceuticals, Inc.
Zentalis reports Q2 2026 results as DENALI Part 2 nears full enrollmentAug 6Regulatory decisionazenosertibSun Pharmaceutical Industries